ADAPY — Adaptimmune Therapeutics plc
$0.03
+$0.00 (+7.14%)
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Market Cap
$7.95M
Forward P/E
N/A
52-Week Range
N/A
ADAPY Price History
Revenue vs. Net Income
$178M
Revenue · FY2024
Annual. Net margin is shown under each year.
Free Cash Flow
-$75.9M
FCF · FY2024
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-35.2%
ROCE · FY2024
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.1x
Assets ÷ liabilities · FY2024
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.5%
CapEx · FY2024
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+25.5%
Dilution · FY2024
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
